Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Reviews Clin Oncol. 2023;20(5):338–49.

Article  Google Scholar 

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

PubMed  Google Scholar 

Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, Meheus F, Verhoeven RHA, Vignat J, Laversanne M, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study. EClinicalMedicine. 2022;47:101404.

Article  PubMed  PubMed Central  Google Scholar 

Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li S, Yu W, Xie F, Luo H, Liu Z, Lv W, Shi D, Yu D, Gao P, Chen C, et al. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 2023;14(1):8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264–79.

PubMed  PubMed Central  Google Scholar 

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

Article  CAS  PubMed  Google Scholar 

Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wong TL, Loh JJ, Lu S, Yan HHN, Siu HC, Xi R, Chan D, Kam MJF, Zhou L, Tong M, et al. ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer. Nat Commun. 2023;14(1):2861.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maiorino L, Daßler-Plenker J, Sun L, Egeblad M. Innate immunity and cancer pathophysiology. Annu Rev Pathol. 2022;17:425–57.

Article  CAS  PubMed  Google Scholar 

Denk D, Greten FR. Inflammation: the incubator of the tumor microenvironment. Trends Cancer. 2022;8(11):901–14.

Article  CAS  PubMed  Google Scholar 

Xu S, Wang Q, Ma W. Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy. Cytokine Growth Factor Rev. 2024;76:12–21.

Article  CAS  PubMed  Google Scholar 

Ding P, Guo H, Sun C, Yang P, Kim NH, Tian Y, Liu Y, Liu P, Li Y, Zhao Q. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study. BMC Gastroenterol. 2022;22(1):121.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020;18(1):360.

Article  PubMed  PubMed Central  Google Scholar 

Hirahara T, Arigami T, Yanagita S, Matsushita D, Uchikado Y, Kita Y, Mori S, Sasaki K, Omoto I, Kurahara H, et al. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer. 2019;19(1):672.

Article  PubMed  PubMed Central  Google Scholar 

Mei P, Feng W, Zhan Y, Guo X. Prognostic value of lymphocyte-to-monocyte ratio in gastric cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol. 2023;14:1321584.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen H, Liu L, Meng Z, Wang P, Chen Z. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158–67.

Article  PubMed  Google Scholar 

Cui S, Cao S, Chen Q, He Q, Lang R. Preoperative systemic inflammatory response index predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation. Front Immunol. 2023;14:1118053.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Z, Ge H, Miao Z, Shao S, Shi H, Dong C. Dynamic changes in the systemic inflammation response index predict the outcome of resectable gastric cancer patients. Front Oncol. 2021;11:577043.

Article  PubMed  PubMed Central  Google Scholar 

Zheng C, Ye S, Liu W, Diao M, Li L. Prognostic value of systemic inflammation response index in hepatoblastoma patients receiving preoperative neoadjuvant chemotherapy. Front Oncol. 2023;13:1276175.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zuo R, Zhu F, Zhang C, Ma J, Chen J, Yue P, Cui J, Wang Y, Chen P. The response prediction and prognostic values of systemic inflammation response index in patients with advanced lung adenocarcinoma. Thorac Cancer. 2023;14(16):1500–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y, Jin M, Shao Y, Xu G. Prognostic Value of the Systemic Inflammation Response Index in Patients with Adenocarcinoma of the Oesophagogastric Junction: A Propensity Score-Matched Analysis. Dis Markers. 2019;2019:4659048.

Article  PubMed  PubMed Central  Google Scholar 

Wu Q, Zhao H. Prognostic and clinicopathological role of pretreatment systemic inflammation response index (SIRI) in gastric cancer: a systematic review and meta-analysis. World J Surg Oncol. 2024;22(1):333.

Article  PubMed  PubMed Central  Google Scholar 

Gao W, Zhang F, Ma T, Hao J. High preoperative fibrinogen and systemic inflammation response index (F-SIRI) predict unfavorable survival of resectable gastric cancer patients. J Gastric Cancer. 2020;20(2):202–11.

Article  PubMed  PubMed Central  Google Scholar 

Chen L, Chen Y, Zhang L, Xue Y, Zhang S, Li X, Song H. In gastric cancer patients receiving neoadjuvant chemotherapy systemic inflammation response index is a useful prognostic indicator. Pathol Oncol Res. 2021;27:1609811.

Article  PubMed  PubMed Central  Google Scholar 

Yazici H, Yegen SC. Is systemic inflammatory response index (SIRI) a reliable tool for prognosis of gastric cancer patients without neoadjuvant therapy? Cureus. 2023;15(3).

Bessède E, Mégraud F. Microbiota and gastric cancer. Sem Cancer Biol. 2022;86(Pt 3):11–7.

Article  Google Scholar 

Bin YL, Hu HS, Tian F, Wen ZH, Yang MF, Wu BH, Wang LS, Yao J, Li DF. Metabolic reprogramming in gastric cancer: Trojan horse effect. Front Oncol. 2021;11:745209.

Article  CAS  PubMed  Google Scholar 

Zeng R, Gou H, Lau HCH, Yu J. Stomach microbiota in gastric cancer development and clinical implications. Gut. 2024;73(12):2062–73.

Article  CAS  PubMed  Google Scholar 

Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, Wu WK, Wong SH, Chen Z, Sung JJY, et al. Mucosal Microbiome dysbiosis in gastric carcinogenesis. Gut. 2018;67(6):1024–32.

Article  CAS  PubMed  Google Scholar 

Yu D, Yang J, Jin M, Zhou B, Shi L, Zhao L, Zhang J, Lin Z, Ren J, Liu L, et al. Fecal Streptococcus alteration is associated with gastric cancer occurrence and liver metastasis. mBio. 2021;12(6):e0299421.

Article  PubMed